The Protocol Review and Monitoring Committee (PRMC) was established at UAMS in 1994 and reviews all clinical studies conducted under the auspices of the Winthrop P. Rockefeller Cancer Institute (Cancer Institute).
All cancer-related clinical protocols must be reviewed and receive full PRMC approval (in addition to IRB approval) before they can be activated and enroll patients. New protocols are approved based on scientific merit, scientific priority, patient availability, and available resources.
Potential industry sponsored trials must be submitted through the Cancer Clinical Trials Office (CCTO).
Investigator initiated trials are required to consult with the Cancer Institute’s biostatistics shared resource group before they can be brought before the PRMC. Please contact Nia Indelicato for more information.
Principal Investigators with potential investigator-initiated studies are encouraged to contact the CCTO for assistance, but they may be submitted directly via email to the PRMC. Please include the following documents with your submission:
- PI Checklist (via redcap survey)
- Please complete the survey and then download a copy of your responses; attach that to the submission email.
- Informed Consent
- Any other relevant documents (investigator brochure, etc.)
For questions, please contact Nia Indelicato, the PRMC administrator.